Avalon Globocare is a real estate services business based in the US. Avalon Globocare shares (AVCO) are listed on the NASDAQ and all prices are listed in US Dollars. Avalon Globocare employs 5 staff and has a trailing 12-month revenue of around $1.4 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.43 |
|---|---|
| 52-week range | $0.00 - $0.00 |
| 50-day moving average | $0.50 |
| 200-day moving average | $0.58 |
| Wall St. target price | N/A |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.10 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.4315 from 2022-12-14
| 1 week (2024-08-27) | N/A |
|---|---|
| 1 month (2024-08-03) | N/A |
| 3 months (2024-06-03) | N/A |
| 6 months (2024-03-03) | N/A |
| 1 year (2023-09-03) | N/A |
|---|---|
| 2 years (2022-09-07) | -14.21% |
| 3 years (2021-09-07) | 0.9 |
| 5 years (2019-09-06) | 1.97 |
| Revenue TTM | $1.4 million |
|---|---|
| Gross profit TTM | $354,055 |
| Return on assets TTM | -47.81% |
| Return on equity TTM | -497.06% |
| Profit margin | 0% |
| Book value | $0.00 |
| Market Capitalization | $52.2 million |
TTM: trailing 12 months
We're not expecting Avalon Globocare to pay a dividend over the next 12 months.
Avalon Globocare's shares were split on a 1:10 basis on 4 January 2023. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Avalon Globocare shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Avalon Globocare shares which in turn could have impacted Avalon Globocare's share price.
Over the last 12 months, Avalon Globocare's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Avalon Globocare's is 0.8063. This would suggest that Avalon Globocare's shares are less volatile than average (for this exchange).
Avalon GloboCare Corp. , together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry.
Use this calculator to quickly see potential outcomes of your options trades.
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.